Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

Bourke, SC; Tomlinson, Mark; Williams, Tim; Bullock, R. E.; Shaw, Pamela J.; Gibson, Gretchen

doi:10.1016/s1474-4422(05)70326-4

Cited by 933 publications

(728 citation statements)

References 37 publications

Supporting

Mentioning

647

Contrasting

Unclassified

Order By: Relevance

“…8 This study shows that NIV tolerance was associated with time spent with S pO 2 Ͻ 90% at night while on NIV. Although differences between tolerant and intolerant subjects were not found in the percentage of subjects in whom effective NIV (as defined in methods section) was achieved, for those subjects with low NIV adherence, no improvement in P aO 2 and P aCO 2 was found, and they presented lower P aO 2 after NIV and worse minimum nocturnal S pO 2 and mean nocturnal S pO 2 while using NIV compared with tolerant subjects. In the same way, the percentage of effective NIV in intolerant subjects was the same upon NIV initiation and after 3 months (85.71%); this means that there was no worsening in the effectiveness of ventilation during this 3-month period to which intolerance might otherwise be attributed.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Tolerance of Volume Control Noninvasive Ventilation in Subjects With Amyotrophic Lateral Sclerosis

et al. 2015

View full text Add to dashboard Cite

BACKGROUND: Noninvasive ventilation (NIV) tolerance has been identified as an independent predictor of survival in amyotrophic lateral sclerosis (ALS). Volume control continuous mandatory ventilation (VC-CMV) NIV has been associated with poor tolerance. The aim of this study was to determine the tolerance of subjects with ALS to VC-CMV NIV. METHODS: This was a prospective study involving subjects with ALS who were treated with VC-CMV NIV. Respiratory and functional parameters were recorded when the subjects began ventilatory support. NIV tolerance was evaluated after 3 months. RESULTS: Eighty-seven subjects with ALS were included. After 3 months, 80 subjects (92%) remained tolerant of NIV. Tolerant subjects presented greater survival (median 22.0 months, 95% CI 14.78 -29.21) than intolerant subjects (median 6.0 months, 95% CI 0.86 -11.13) (P ‫؍‬ .03). The variables that best predicted NIV tolerance were mechanically assisted cough peak flow (P ‫؍‬ .01) and percentage of time spent with S pO 2 < 90% at night while on NIV (P ‫؍‬ .03) CONCLUSIONS: VC-CMV NIV provides high rates of NIV tolerance in subjects with ALS. Mechanically assisted cough peak flow and percentage of time spent with S pO 2 < 90% at night while using NIV are the 2 factors associated with tolerance of VC-CMV NIV in subjects with ALS.

show abstract

Section: Discussionmentioning

confidence: 87%

“…The percentage of time spent with S pO 2 Ͻ 90% at night, the minimum nocturnal S pO 2 , and the mean nocturnal S pO 2 were recorded while the subject was spontaneously breathing.…”

Section: Clinical and Functional Impairment Assessmentmentioning

confidence: 99%

Tolerance of Volume Control Noninvasive Ventilation in Subjects With Amyotrophic Lateral Sclerosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In a recent study [30], the median tracheostomy-free survival from symptom onset was 28 months in NIV-treated patients, compared to 15 months for untreated patients, and the benefit persisted after adjusting for age, gender, riluzole use and gastrostomy use. However, the only randomized controlled trial of NIV did not support this finding [33].…”

Section: Discussionmentioning

confidence: 98%

Multidisciplinary Care Improves Survival of Patients with Amyotrophic Lateral Sclerosis in the Unique Health System (SUS) in Brazil

Moura¹,

Casulari²,

Novaes³

2017

J Neurol Disord

View full text Add to dashboard Cite

Objective: To determine the effectiveness of multi-professional palliative care in patients with amyotrophic lateral sclerosis in Brazilian public health system. Methods:Historic-control study before and after the Reference Center, with records and mortality data of 302 patients treated with riluzole between 2005 and 2015, were retrospectively evaluated and survival curves were analyzed.Results: There were 181 men (59.9%) and 121 women (40.1%) with a diagnostic delay time of 28.1 months for spinal-onset and 20.1 months for bulbar-onset (p=0.003) and a mean survival of 61.7 ± 5.4 months for spinal-onset and 38 ± 3.5 months for bulbar-onset (p=0.01). Electromyography did not confirm the diagnosis in 55.6% of the suspected spinal-onset cases and 36.1% of the bulbar-onset. From 2005 to 2011, mean survival was 33.6 ± 2.4 months, and after multidisciplinary care, 72.2 ± 7.2 months (log-rank: 0.0001). Conclusion:Multidisciplinary care improves the survival of amyotrophic lateral sclerosis patients in the Unique Health System.

show abstract

“…1 A large number of observational studies and a small number of randomized trials 2,3 have confirmed the effectiveness of noninvasive ventilation (NIV) in these individuals. Improvement in survival, 2,4-9 daytime symptoms of hypoventilation, quality of life, and arterial blood gases have all been documented.…”

Section: Introductionmentioning

confidence: 99%

Data Downloads for Effective Noninvasive Ventilation in Patients With Neuromuscular Respiratory Failure

2013

View full text Add to dashboard Cite

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

Cited by 933 publications

References 37 publications

Tolerance of Volume Control Noninvasive Ventilation in Subjects With Amyotrophic Lateral Sclerosis

Tolerance of Volume Control Noninvasive Ventilation in Subjects With Amyotrophic Lateral Sclerosis

Multidisciplinary Care Improves Survival of Patients with Amyotrophic Lateral Sclerosis in the Unique Health System (SUS) in Brazil

Data Downloads for Effective Noninvasive Ventilation in Patients With Neuromuscular Respiratory Failure

Contact Info

Product

Resources

About